<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03695835</url>
  </required_header>
  <id_info>
    <org_study_id>NIRPA</org_study_id>
    <nct_id>NCT03695835</nct_id>
  </id_info>
  <brief_title>A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen.</brief_title>
  <acronym>NIRPA</acronym>
  <official_title>A Retrospective and Prospective Study of a New Immunotherapy Regimen (MyVaccx) for Patients With Adenocarcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gary Onik MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gary Onik MD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A retrospective and prospective data collection study on 27 consecutive subjects with
      adenocarcinoma who were treated using the MyVaccx system by Dr. Gary Onik. Retrospective data
      were collected on the treatment with the immunotherapy system and prospective data will be
      collected as they are prospectively monitored through their normal standard of care for their
      original cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 11, 2018</start_date>
  <completion_date type="Actual">June 17, 2020</completion_date>
  <primary_completion_date type="Actual">July 8, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MyVaccx immunotherapy treatment impact on late stage cancer disease</measure>
    <time_frame>From date of treatment until the date of death from any cause up to 60 months</time_frame>
    <description>Time to death after the start of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MyVaccx immunotherapy treatment impact on late stage cancer disease</measure>
    <time_frame>Time to progression after a complete or partial response up to 60 months</time_frame>
    <description>Complete and partial response to treatment based on the iRESIST criteria</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">27</enrollment>
  <condition>Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Adenocarcinoma treated with MyVaccx</arm_group_label>
    <description>MyVaccx combines tumor ablation and immunotherapeutic agents for treatment of late stage cancer disease..</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunotherapeutic Agents</intervention_name>
    <description>Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents</description>
    <arm_group_label>Adenocarcinoma treated with MyVaccx</arm_group_label>
    <other_name>Yervoy, Keytruda, Leukine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ablation</intervention_name>
    <description>Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents</description>
    <arm_group_label>Adenocarcinoma treated with MyVaccx</arm_group_label>
    <other_name>Cryo and radio frequency (RF) ablation</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with adenocarcinoma treated with the MyVaccx System through the Center for High
        Risk and Recurrent Prostate Cancer.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment with the MyVaccx System

          -  Greater than 18 years of age

          -  Signature of the informed consent

        Exclusion Criteria:

          -  2 subjects treated with the MyVaccx System with known visceral disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Center for High Risk and Recurrent Prostate Cancer</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 28, 2018</study_first_submitted>
  <study_first_submitted_qc>October 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2018</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>lung cancer</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Results will be published in a medical journal.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>After retrospective data collection is completed.</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT03695835/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

